RESEARCH ARTICLE

Increased Expression of Interferon Signaling Genes in the Bone Marrow Microenvironment of Myelodysplastic Syndromes

Miyoung Kim¹,², Seungwoo Hwang³, Kiejung Park³, Seon Young Kim², Young Kyung Lee¹,⁴, Dong Soon Lee²,⁵

¹ Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea, ² Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, ³ Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea, 4 Department of Laboratory Medicine, Hallym University College of Medicine, Anyang, Republic of Korea, 5 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

* soonlee@snu.ac.kr

Abstract

Introduction

The bone marrow (BM) microenvironment plays an important role in the pathogenesis of myelodysplastic syndromes (MDS) through a reciprocal interaction with resident BM hematopoietic cells. We investigated the differences between BM mesenchymal stromal cells (MSCs) in MDS and normal individuals and identified genes involved in such differences.

Materials and Methods

BM-derived MSCs from 7 MDS patients (3 RCMD, 3 RAEB-1, and 1 RAEB-2) and 7 controls were cultured. Global gene expression was analyzed using a microarray.

Result

We found 314 differentially expressed genes (DEGs) in RCMD vs. control, 68 in RAEB vs. control, and 51 in RAEB vs. RCMD. All comparisons were clearly separated from one another by hierarchical clustering. The overall similarity between differential expression signatures from the RCMD vs. control comparison and the RAEB vs. control comparison was highly significant (p = 0), which indicates a common transcriptomic response in these two MDS subtypes. RCMD and RAEB simultaneously showed an up-regulation of interferon alpha/beta signaling and the ISG15 antiviral mechanism, and a significant fraction of the RAEB vs. control DEGs were also putative targets of transcription factors IRF and ICSBP. Pathways that involved RNA polymerases I and III and mitochondrial transcription were down-regulated in RAEB compared to RCMD.
Conclusion

Gene expression in the MDS BM microenvironment was different from that in normal BM and exhibited altered expression according to disease progression. The present study provides genetic evidence that inflammation and immune dysregulation responses that involve the interferon signaling pathway in the BM microenvironment are associated with MDS pathogenesis, which suggests BM MSCs as a possible therapeutic target in MDS.

Introduction

Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal stem cell disorders characterized by peripheral cytopenia, paradoxical hypercellular bone marrow (BM), and variable degrees of increased blasts [1,2]. The symptoms of MDS are a result of ineffective hematopoiesis, which leads to a peripheral deficiency of maturing blood cells, dysplastic features of hematopoietic cells, dysregulation of the cell cycle, and uncontrolled proliferation. The development of MDS likely occurs through multiple evolutionary stages, and the clinical course is divided into several distinct phases depending on the number of lineages involved in dysplasia and the percentage of blasts in the BM [1,2].

Genetic alterations in hematopoietic cells promote the initiation and progression of MDS. Approximately 40–50% of de novo MDS cases show cytogenetic abnormalities, including partial or complete chromosome loss involving chromosomes 5, 7, 20, 11, and Y [1–3]. These cytogenetic abnormalities are the primary molecular markers or inducers of somatic DNA injury, defective DNA repair, impaired immune surveillance, and dysregulated signal transduction [3,4]. The prognostic importance of these abnormalities is well established, and they are incorporated as key components in the prognostic scoring system for MDS [1,5]. Gene expression studies in MDS cases showed altered expressions of oncogenes (N-RAS, WT1) and genes involved in cell cycle regulation (CDKN2B, EVI-1), apoptosis (BCL2, C-MYC, TP53), DNA methylation (DNMT3A, TET2, IDH1/IDH2), and histone deacetylation (H3K27, EZH2, UTX, ASXL1) [3–6]. An overexpression of N-RAS or WT1 was observed in advanced stages of MDS, and a down-regulation of CDKN2B as a result of promoter hypermethylation was associated with leukemic transformation in MDS [4,7–10].

Nevertheless, previous studies on cytogenetic or molecular genetic alterations of MDS hematopoietic cells do not completely delineate the pathogenesis of this disease, which suggests that the reciprocal interaction between hematopoietic elements and the BM microenvironment might also contribute to MDS pathogenesis [11–15]. Therefore, the role of BM mesenchymal stromal cells (MSCs), which are the main constituents of the BM microenvironment, deserves attention. Previous functional studies primarily focused on disturbances of cytokine production or the supporting ability of the BM microenvironment. The results suggested that the BM microenvironment contributes to the apoptosis of BM hematopoietic cells and the selective growth advantage of CD34+ blasts in MDS [15–17]. Several studies elucidated an altered expression of targeted genes in MDS BM MSCs, but only one published study reported the global gene expression profile of pediatric MDS BM MSCs [18]. However, the pathogenesis and phenotype of pediatric MDS are different from those of adult MDS (inherited BM failure syndrome vs. acquired preleukemic condition, respectively) [1].

We hypothesize that gene expression changes in the BM microenvironment play a fundamental role in the development and progression of MDS. We applied global gene expression profiling to BM MSCs of adult de novo MDS patients and performed pathway analyses to gain...
insight into the expected consequences of altered gene expression and investigate whether and how the gene expression profile of MDS BM MSCs is distinct from normal individuals. The gene expression profiles of BM MSCs from the RCMD and RAEB subtypes were also directly compared to identify the genes responsible for the progression of the MDS.

**Materials and Methods**

1. **Patients**

The study included 7 adults who were referred for lymphoma staging with no evidence of BM involvement as controls and 7 adults who were diagnosed as de novo MDS cases in the Seoul National University Hospital from March 2010 to September 2011. The histopathologic diagnosis of primary site in control population include diffuse large B-cell lymphoma (control01 and control02), extranodal marginal zone B-cell lymphoma of mucosa-associated tissue (control04, control05, control06 and control07), and lymphadenitis (control03). The presence of lymphoma cells in the 7 patients who were referred for lymphoma staging was excluded by thorough (i) morphological examination of BM aspirates and BM biopsy sections and immunohistochemical stains for lymphoid cells (CD3, CD20, CD79a, etc.) as well as (ii) immunoglobulin heavy chain gene and immunoglobulin light chain (kappa) gene rearrangement tests [19,20,21]. All 7 patients showed a normal karyotype in BM, and none of them had a history of treatment for lymphoma. MDS patients included 3 RCMD, 3 RAEB-1, and 1 RAEB-2 (6 males and 1 female, age 41–73 years) according to the WHO 2008 classification [1]. The diagnosis of MDS was made based on the following clinical and laboratory findings: (i) clinical symptoms and signs related to cytopenia; (ii) CBC profile, including WBC differential count; (iii) morphological examination of peripheral blood smear, BM aspiration and biopsy; (iv) BM differential count; and (v) conventional karyotyping. The baseline demographic and laboratory findings are summarized in Table 1. BM aspirates obtained at the time of initial diagnosis were used to establish adherent MSC layers. All participants provided written informed consent to participate in this study. The Institutional Research Board of Seoul National University Hospital approved the study (IRB No. C-1008-012-326).

2. **Establishment of adherent MSC layers**

Heparinized or EDTA-anticoagulated BM aspirates were used after centrifugation at 2000 rpm for 5 min. The buffy coat layer was mixed with 5 mL of pre-warmed ACK lysis buffer (Lonza, Walkersville, MD, USA), incubated for 5–10 min, and centrifuged at 1200 rpm for 5 min. The supernatant was aspirated, cells were washed with 10 mL of phosphate-buffered saline (PBS), and the mixture was centrifuged at 1200 rpm for 5 min. The supernatant was aspirated, and the cell pellet was mixed with 1.2 mL of pre-warmed MLR media composed of RPMI1640 media (JBI, Seoul, South Korea), 10% FBS (Gibco, Grand Island, NY, USA), 100 units/mL of an antibiotic-antimycotic agent (Gibco), 10 mM HEPES (Gibco), 1 mM sodium pyruvate (Gibco), 4.5 g/L glucose (Gibco), and 0.05 mM 2-mercaptoethanol (Amresco, Solon, OH, USA). The cells were plated onto 20 mm×20 mm glass slides in two 6-well plates (12 wells), and the plates were incubated at 37°C in a 5% CO₂ incubator until adherent cells (considered BM MSCs) were observed using phase-contrast microscopy. We replaced the culture media every 2–3 days when the confluency of adherent cells reached 30–40%. The cells were harvested at 70–80% confluency. The medium was aspirated, and adherent cells were washed with 2 mL of PBS. The cells were incubated with 500 μL of EDTA–trypsin until the adherent cells detached (~ 3–5 min) and mixed with 5 mL of MLR culture media. The mixture was transferred to a 50 mL tube and centrifuged at 1200 rpm for 5 min. The supernatant was removed, the cell pellet was mixed with 10 mL of MLR media, plated onto culture dishes, and incubated under the
same conditions (37°C, 5% CO2). Cell pellets were mixed with 1 mL of PBS after 3 or 4 passages, counted (usually 1×10^5 – 1×10^6) and stored at −70°C or −140°C in DMSO and 20% FBS.

3. Immunophenotypic characterization of MSCs

Surface antigen expression was monitored by flow cytometry using Navios (Beckman Coulter, Brea, CA, USA) and analyzed using Kaluza software (Beckman Coulter). The following antibodies were used: phycoerythrin-cyanin 5 (PC5) mouse anti-human CD34 (581, Beckman Coulter), allophycocyanin (APC) mouse anti-human CD45 (J.33, Beckman Coulter), fluorescein isothiocyanate (FITC, Beckman Coulter) mouse anti-human CD29 (4B4LDC9LDH8, Beckman Coulter), FITC mouse anti-human CD44 (J.173, Beckman Coulter), phycoerythrin (PE) mouse anti-human CD90 (Thy1/310, Beckman Coulter), and PE mouse anti-human CD105 (1G2, Beckman Coulter) [22,23]. More than 5000 labeled cells were acquired and analyzed.

4. Gene expression microarray

4.1. RNA preparation. Total RNA was extracted using Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA) and purified using RNeasy columns (Qiagen, Valencia, CA, USA) according to the manufacturers’ protocols. After DNase digestion and clean-up procedures, RNA samples were quantified, aliquoted, and stored at −80°C until used. For quality control, RNA

| Case No. (Sex/Age) | Hb (g/dL)—WBC (002FμL)—PLT (×10^3/μL) | Diagnosis | Cellularity (%) | Karyotype |
|--------------------|---------------------------------------|-----------|----------------|-----------|
| RCMD01 (M/41)      | 5.8–4320–100 | MDS, R CMD | 90–100 | 46,XY[20] |
| RCMD02 (M/65)      | 8.6–6800–29 | MDS, R CMD | 90–100 | 46,XY[20] |
| RCMD03 (F/69)      | 9.1–2200–53 | MDS, R CMD | 80–90 | 46,XX,9qh-[20] |
| RAEB01 (M/73)      | 7.2–8300–108 | MDS, RA EB-2 | 70–80 | 46,XY,del(20)(q11.2q13.1)[19]/46,XY[1] |
| RAEB02 (M/73)      | 8.5–1610–186 | MDS, RA EB-1 | 0–10 | 45,X,-Y[6]/46,XY,add(3)(q?25),del(5)(q?13),add(16)(q?22)[2]/46,XY[13] |
| RAEB03 (M/58)      | 8.0–2650–171 | MDS, RA EB-1 | 70–80 | 54–57,XY,+Y,+1,+add(4)(q37),+add(6)(q13),-8,+9,+9,del(11)(p11.2),-13,add (15)(p10),-17,add(19)(q13.3),+20,+21,+22,+22,+3~6mar,inc[cp6]/46,XY[14] |
| RAEB04 (M/58)      | 10.1–6600–37 | MDS, RA EB-1 | 90–100 | 47,XY,+8[4]/46,XY[16] |
| Control01 (M/43)   | 17.0–5700–290 | Normal marrow | 40–50 | 46,XY[20] |
| Control02 (M/58)   | 13.3–6990–374 | Normal marrow | 50–60 | 46,XY[20] |
| Control03 (M/34)   | 13.7–8600–240 | Normal marrow | 50–60 | 46,XY[20] |
| Control04 (F/29)   | 10.2–5260–246 | Normal marrow | 20–30 | 46,XY[20] |
| Control05 (M/51)   | 13.8–3840–184 | Normal marrow | 30–40 | 46,XY[20] |
| Control06 (F/48)   | 10.6–10207–409 | Normal marrow | 30–40 | 46,XY[20] |
| Control07 (M/57)   | 15.1–6410–171 | Normal marrow | 50–60 | 46,XY[20] |

de:10.1371/journal.pone.0120602.t001
purity and integrity were evaluated using denaturing gel electrophoresis and an OD 260/280 ratio on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).

4.2. Labeling and purification. Total RNA was amplified and purified using the Ambion Illumina RNA amplification kit (Ambion, Austin, TX, USA) to yield biotinylated cRNA according to the manufacturer’s instructions. Briefly, 550 ng of total RNA was reverse-transcribed using a T7 oligo(dT) primer. Second-strand gene expression was synthesized, transcribed in vitro, and labeled with biotin-NTPs. After purification, the cRNA was quantified using an ND-1000 Spectrophotometer (NanoDrop, Wilmington, DE, USA).

4.3. Hybridization and data export. Labeled cRNA samples (750 ng) were hybridized to each HumanHT-12 v4 Expression BeadChip for 16–18 h at 58°C according to the manufacturer’s instructions (Illumina, San Diego, CA, USA). The array uses 47,231 probes to detect the expression of 34,694 genes. Array signals were detected using Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadArray manual. Arrays were scanned with an Illumina BeadArray Reader confocal scanner according to the manufacturer’s instructions. Array data export processing and analyses were performed using Illumina BeadStudio v3.1.3 (Gene Expression Module v3.3.8).

4.4. Raw data preparation and statistical analysis. The hybridization quality and overall chip performance were monitored by visual inspection of both internal quality control checks and the raw-scan data. Raw data were extracted using the software provided by the manufacturer (Illumina GenomeStudio v2009.2, Gene Expression Module v1.5.4).

4.5. Microarray data preprocessing. The summarized expression level (AVG_Signal) of each probe was normalized across samples using the quantile method and log2-transformed in the lumi R package [24]. Probe annotation was also retrieved with the lumi R package. Expression data from probes without Entrez Gene ID annotation or correspondence to protein-coding genes were discarded. Expression levels from multiple probes representing the same gene were averaged to yield gene-level expression profiles for 18,581 unique genes.

4.6. Differential expression and clustering analysis. Differentially expressed genes (DEGs) were selected using two criteria: Student’s t-test p-value < 0.01 and fold change > 1.5. A Venn diagram of DEGs was created in Cytoscape [25] and its MultiColoredNodes plug-in [26]. The overall similarity of differential expression signatures between RCMD vs. control and RAEB vs. control was assessed using the OrderedList R package [27], which does not rely on a simple overlap of DEGs but instead considers the complete ordering of all genes in the two differential expression signatures to assess their overall similarity. Hierarchical clustering was performed in the EMA R package using the average linkage method with a Pearson centered correlation as a similarity metric to examine how well the sample group DEG expression profiles were separable [28]. The expression profile of each gene was standardized prior to clustering using a z-transformation such that the row mean and variance were set to 0 and 1, respectively.

4.7. Functional enrichment analysis. Functional enrichment analysis was used to identify prevalent biological themes among the DEGs. Functional enrichment analysis with respect to reactome pathways was performed on the KOBAS web server [29,30] using significance criteria of a gene count ≥ 3 and a p-value < 0.01. To simplify the presentation of the results, if several pathways were identified as significant and if they contained the same set of pathway member DEGs, the pathway at the lowest level was selected over pathways at higher levels. For example, interferon signaling was selected over cytokine signaling in the immune system if both pathways contained the same set of member DEGs. Functional enrichment analysis with respect to transcription factor binding sites was performed on the TransFind web server using default options [31].
4.8. Data repository. The microarray data are available at Gene Expression Omnibus under the accession number GSE61853 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=chqncqaiztornql&acc=GSE61853 or http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61853).

Results

1. Immunophenotypic characterization of MSCs

The majority of the harvested cells from adherent cell layers showed low to intermediate forward scatter and low side scatter in flow cytometric analyses. These cells were positive for CD29, CD44, CD90, and CD105 (known MSC markers) but not CD34 or CD45 (known hematopoietic markers), which is consistent with an MSC immunophenotype (Supplementary Data).

2. Differential expression and clustering analysis

Differential expression was tested for all possible pairwise comparisons between sample groups: (i) RCMD vs. control, (ii) RAEB vs. control, and (iii) RAEB vs. RCMD (Fig. 1). A total of 413 DEGs were identified: 314 in RCMD vs. control (134 overexpressed and 180 underexpressed), 68 in RAEB vs. control (34 overexpressed and 34 underexpressed), and 51 in RAEB vs. RCMD (45 overexpressed and 6 underexpressed). The list of DEGs in each comparison is provided in S1 Data. The number of simultaneous DEGs in at least two comparisons was 3 for RAEB vs. control and RAEB vs. control, 4 for RCMD vs. control and RAEB vs. RCMD, and 13 for RCMD vs. control and RAEB vs. control. The overall similarity between differential expression signatures from the RCMD vs. control and RAEB vs. control comparisons was significant ($p$-value of 0). Hierarchical clustering based on DEG expression profiles clearly separated RCMD from control, RAEB from control, and RCMD from RAEB (Fig. 2).

3. Deregulated pathways and transcription factor targets

Compared to control cases, both RCMD and RAEB cases showed a similarly strong up-regulation of interferon signaling pathways, including interferon alpha/beta signaling and the ISG15 antiviral mechanism (Table 2 and Fig. 3). Compared to RCMD, RAEB showed a down-regulation of RNA polymerase I, RNA polymerase III, mitochondrial transcription, GTP hydrolysis, and joining of the 60S ribosomal subunit pathways. Compared to the control, target genes of the transcription factors interferon regulatory factor (IRF) and interferon consensus sequence-binding protein (ICSBP; also IRF8) were up-regulated in RAEB (Table 3). Compared to RCMD, RAEB exhibited a down-regulation of target genes of transcription factor Zic family member 1 (ZIC1), stimulated by retinoic acid 13 (STRA13), upstream stimulatory factor (USF), and aryl hydrocarbon receptor-hypoxia inducible factor (AhR-HIF).

Discussion

The present study determined differences in BM MSC gene expression profiles and the involved pathways between MDS patients and normal individuals. Malignant cells may arise from intrinsic changes, whereas oncogenesis and neoplasm progression may depend on reciprocal autocrine and paracrine communication with the surrounding microenvironment [14,32,33]. The BM microenvironment may play a pivotal role in the pathophysiology of MDS. Several functional studies showed that the BM microenvironment contributes to MDS. Apoptosis of F-36P cells (a MDS cell line) was augmented in the MDS BM microenvironment compared to the normal BM microenvironment [15]. Furthermore, the MDS BM
microenvironment inhibited the growth of resident BM hematopoietic cells, likely through an elevated secretion of interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6) [13,34]. We performed global gene expression profiling of MDS BM MSCs at different disease stages using Illumina BeadArray to improve our understanding of the role of the BM microenvironment in MDS. The combination of pathway analyses and transcription factor binding site analyses facilitated the identification of key pathways and transcription factors that are presumably perturbed in RCMD and RAEB MSCs compared to normal MSCs or between these two different disease stages.

Hierarchical clustering showed that the gene expression profiles in MDS BM MSCs and control BM MSCs were different. Clear separations were observed between MDS BM MSCs and control BM MSCs in two independent pairwise comparisons: RCMD vs. control and RAEB vs. control.
RAEB vs. control. Furthermore, similarity analyses revealed that the overall expression signatures of these two MDS subgroups were significantly similar to each other in their differential expression ranks \( (p = 0) \). Only small overlaps between the two DEG sets were observed despite the strong overall similarity between the differential expression signatures of the two MDS subtypes (Fig. 1). A small overlap problem commonly occurs in gene expression studies because for a gene to be in the intersection of two DEG sets, it must pass the differential expression test two independent times. The probability of simultaneously passing both tests is low because it is equal to the product of the two individual tests’ probabilities, which leads to a small overlap \[^{[35]}\]. Nevertheless, Fig. 1 shows that most of the DEGs that were specific to either RCMD or RAEB were enriched in the interferon pathway.

### Table 2. Significantly enriched reactome pathways in the differentially expressed genes (DEGs).

| Reactome pathway                               | \( p \)-value | DEG pathway members                                           |
|------------------------------------------------|---------------|---------------------------------------------------------------|
| Up-regulated in RCMD vs. control               |               |                                                               |
| Interferon alpha/beta signaling                | 4.66E-10      | IRF7 IFITM3 IFI35 IFITM1 IFITM2 MX2 MX1 IFI6 ISG15            |
| Interferon signaling                           | 3.05E-09      | IRF7 AAAS IFITM3 IFI35 HLA-DRB4 IFITM1 IFITM2 HLA-DRA MX2 MX1 IFI6 ISG15 |
| ISG15 antiviral mechanism                      | 1.78E-03      | AAAS MX1 MX2 ISG15                                           |
| Immune system                                  | 4.05E-03      | IRF7 AAAS MX1 CD74 IFITM3 IFI35 HLA-DRB4 PSMC3 IFITM1 IFITM2 HLA-DRA MX2 CALR UBE2M IFI6 ISG15 |
| Interferon gamma signaling                     | 9.01E-03      | IRF7 IFITM3 IFI35 MX1 IFI6 MX2                              |
| Up-regulated in RAEB vs. control               |               |                                                               |
| Interferon alpha/beta signaling                | 5.70E-12      | IRF7 IFITM3 IFI35 ISG15 MX1 IFI6 MX2                        |
| ISG15 antiviral mechanism                      | 2.06E-04      | MX1 ISG15 MX2                                               |
| Up-regulated in RAEB vs. RCMD                  |               |                                                               |
| None                                           |               |                                                               |
| Down-regulated in RCMD vs. control             |               |                                                               |
| Membrane trafficking                           | 2.64E-05      | YWHAQ AP3S1 YIPF6 VPS4B CLINT1 STAM VAMP2                   |
| Golgi-associated vesicle biogenesis            | 1.29E-04      | YIPF6 AP3S1 CLINT1 VAMP2                                     |
| The citric acid (TCA) cycle and respiratory electron transport | 2.27E-03 | ETFDH ETFA NDUFB5 MPC2                                      |
| Respiratory electron transport                  | 4.58E-03      | ETFDH ETFA NDUFB5                                           |
| Down-regulated in RAEB vs. control             |               |                                                               |
| None                                           |               |                                                               |
| Down-regulated in RAEB vs. RCMD                |               |                                                               |
| RNA polymerase I, RNA polymerase III, and mitochondrial transcription | 1.57E-03 | TAF1B LZTS1 MNAT1                                            |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 5.55E-03 | EIF1AX EIF3A RPL31                                           |
RAEB showed concordant differential expression in the two MDS subtypes, which indicates a common transcriptomic response. Pathway analyses showed that the interferon signaling pathway (interferon alpha/beta signaling and the ISG15 antiviral mechanism) was commonly deregulated in the two comparisons. Similarly, transcription factor binding site analysis revealed

Table 3. Significantly enriched transcription factor binding sites in the promoter sequences of the differentially expressed genes (DEGs).

| TF* name                        | TFBS ID†      | FDR‡  | Target genes in DEGs                                      |
|---------------------------------|---------------|-------|-----------------------------------------------------------|
| Up-regulated in RCMD vs. control| None          |       |                                                           |
| Up-regulated in RAEB vs. control| ICSBP (interferon consensus sequence-binding protein, IRF8) | V$ICSBP_Q6 2.18E-04 | UCRP IFI6 IFIT1 IFM3 IN35 MX2 PAR10 |
|                                 | IRF (interferon regulatory factor) | V$IRF_Q6 1.29E-02 | UCRP IFI6 IFIT1 IN35 MX2 PAR10 |
| Up-regulated in RAEB vs. RCMD   | None          |       |                                                           |
| Down-regulated in RCMD vs. control| None          |       |                                                           |
| Down-regulated in RAEB vs. control| None          |       |                                                           |
| Down-regulated in RAEB vs. RCMD | ZIC1 (Zic family member 1) | V$ZIC1_01 3.87E-03 | B1AJJ9 FHAD1 CE350 PTN7 PDCD4 PLEC2 ACHB4 BAG2 |
|                                 | STRA13 (stimulated by retinoic acid 13) | V$STRA13_01 3.87E-03 | FA21A YAP1 QCR2 ZCH18 TXNL1 MUC24 VATH |
|                                 | USF (upstream stimulatory factor) | V$USF_01 1.64E-02 | FA21A EIF3 ZCH18 RBX1 MUC24 VATH |
|                                 | AhR-HIF (aryl hydrocarbon receptor-hypoxia inducible factor) | V$AHHRHIF_Q6 1.64E-02 | FA21A TEBP CL023 RGRF1 TXNL1 UGDH |

*TF: Transcription factor  
†TFBS: transcription factor binding site  
‡FDR: false discovery rate

doi:10.1371/journal.pone.0120602.t003
that interferon regulatory factor (IRF) and ICSBP (one of 9 IRFs) targeted a significant fraction of the up-regulated DEGs in RAEB. IRFs play diverse roles in innate and adaptive immunity by regulating interferons [36–39]. Cytopenias in MDS may be cytokine induced and associated with T-cell-mediated myelosuppression [40–42]. A derangement of proinflammatory cytokines, including TNF-\(\alpha\), leukemia inhibitory factor, IL-32, IL-1\(\beta\), IL-6, and hepatocyte growth factor, was observed in the MDS BM microenvironment. These mechanisms suggest that improvements in the impaired erythroid and myeloid colony formation of early hematopoietic progenitors by immune modulating drugs, such as Lenalidomide, may be useful in low-risk MDS [43]. The altered expression of genes associated with interferon signaling of MDS BM MSCs shows that these factors participate in the deregulated inflammatory and immune status of MDS (both RCMD and RAEB), which likely affects and is affected by ineffective hematopoiesis to cause intramedullary apoptosis and an abnormal differentiation/maturation of resident hematopoietic precursors.

We attempted to determine whether similar changes were observed in BM hematopoietic cells in parallel with BM MSCs in MDS patients. However, we could not analyze the gene expression profile of corresponding BM hematopoietic cells. Instead, we compared our data with previously published data (publicly available in Gene Expression Omnibus) of gene expression in MDS CD34+ hematopoietic cells (shown in S1 Data) [44]. The interferon signaling pathway was commonly up-regulated in MDS BM CD34+ cells and BM MSCs, although the altered genes were not identical. The up-regulation of interferon signaling pathways in BM MSCs and BM hematopoietic cells might result from a reciprocal interaction between these cells during the development of the MDS.

Clustering analyses differentiated the gene expression profile of RCMD BM MSCs from RAEB BM MSCs, despite the similar overall differential expression signatures of RCMD vs. control and RAEB vs. control (\(p = 0\)) and a simultaneous up-regulation of immune (interferon) pathways. These results indicate that gene expression alterations in BM MSCs are involved in disease progression in MDS. The main features of early and late MDS are distinct: ineffective hematopoiesis and bone marrow failure are dominant in RCMD, and a selective growth advantage of blasts is prominent in RAEB [1,7]. Consistent with our hypothesis, direct comparisons of the gene expression profiles of RCMD BM MSCs and RAEB BM MSCs showed that RNA polymerase I, RNA polymerase III, mitochondrial transcription, GTP hydrolysis, and joining of the 60S ribosomal subunit were down-regulated in RAEB BM MSCs. We were unable to directly compare our data with previous data because this study is the first of its type.

The relationship between RNA polymerase and MDS pathogenesis is not well studied. We infer that a deregulation of the RNA polymerase pathway would alter the normal transcription of critical genes, such as tumor suppressor genes, because RNA polymerase plays a role in the modulation of DNA transcription. Recently, mutations in epigenetic regulators (CDKN2B and DNMT3A) and RNA splicing pathway members (SF3B1, U2AF1, ZRSR2, and SRSF2) were recurrently observed in MDS BM hematopoietic cells, and these mutations may be related to the biology and prognosis of MDS [45,46]. Studies on other tumors indicated an association between disease pathogenesis and changes in RNA transcription in tumors and tumor microenvironments. One study on ovarian cancer observed a transcriptional modification resulting from pre-mRNA alternative splicing in cancer cells and the tumor microenvironment [47]. Trabectedin, which is an anti-neoplastic drug for soft tissue sarcoma, interacts with proteins at the site of RNA polymerase II in cancer cells and cells in the tumor microenvironment [48]. Notably, mitochondrial transcription is highlighted in genetic changes in some MDSs (especially RARS). The ringed sideroblasts are erythroblasts that accumulate iron within mitochondria, which indicates a disturbed mitochondrial iron metabolism because of a malfunction in the mitochondrial respiratory chain that may be related to MDS pathogenesis [1,49]. One study of
mitochondrial DNA in MDS CD34+ cells using real-time RT-PCR observed a significant reduction in mitochondrial-encoded gene expression in MDS compared to normal controls [50]. A mitochondrial defect has not been studied in the MDS BM microenvironment, and our results demonstrate the possibility that MDS BM MSCs have mitochondrial abnormalities in parallel with resident BM hematopoietic cells.

The down-regulation of DEGs targeted by transcription factors, including ZIC1, STRA13, USF and AhR-HIF, in RAEB BM MSCs compared to RCMD BM MSCs suggests another role of BM MSCs in the progression of MDS. The clinical relevance of this observation is not clear, but we hypothesize that it is associated with features that differ between early and late MDS. The expression of STRA13, USF and AhR-HIF is related to growth arrest and inhibits cell differentiation and proliferation [51–59]. Therefore, RCMD BM MSCs are not competent for differentiation and proliferation, and these cells cannot properly support resident apoptotic hematopoietic cells. In contrast, RAEB BM MSCs may be more supportive for resident cells, including blasts with growth advantages. We suggest that the observations in the pathway analysis and transcription factor binding site analysis in combination with other changes in gene expression analysis lead to complex alterations in MDS BM MSCs rather than resulting in one simple consequence.

One limitation of our study is the small number of samples. Only 7 controls and 7 patients, consisting of 3 RCMD and 4 RAEB patients, were included. A study using a larger sample might provide more reliable information on alterations in gene expression in the MDS BM microenvironment. Nevertheless, our data are likely representative and valid because the gene expression profile was consistent between samples in each group and each subgroup: (i) the gene expression profile was similar among patients but distinguished from the control group; and (ii) the gene expression profile was consistent between patients in each stage (either RCMD or RAEB), but it was different between groups. Above all, our study is noteworthy because there are no published global gene expression profiles of adult MDS BM MSCs. Subsequent studies using a larger study population will provide a better understanding of the relevance of the BM microenvironment in the pathogenesis of MDS.

In summary, gene expression profiles in MDS BM and normal BM microenvironments were distinct. An up-regulation of interferon signaling pathways was exhibited in MDS, which provides evidence for an association of MDS with chronic inflammation or an altered immune system. The down-regulation of several pathways involving RNA polymerase and mitochondria in RAEB compared to RCMD suggests that the BM microenvironment is also involved in MDS progression. Changes in the BM microenvironment according to disease progression are an attractive target for future therapeutic strategies.

Supporting Information

S1 Data. Supporting information.

(DOCX)

Author Contributions

Conceived and designed the experiments: DSL MK. Performed the experiments: MK SYK. Analyzed the data: MK SH KP. Contributed reagents/materials/analysis tools: DSL. Wrote the paper: DSL MK YKL.

References

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008 IARC Press, Lyon.
2. Tefferi A, Vardiman JW. Myelodysplastic Syndromes. N Engl J Med 2009; 361:1872–1885 doi: 10.1056/NEJMra0902908 PMID: 19890130
3. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol. 2008 Sep; 142(5):695–708. doi: 10.1111/j.1365-2141.2008.07245.x PMID: 18504941
4. Nishino HT, Chang CC. Myelodysplastic syndromes: clinicopathologic features, pathobiology, and molecular pathogenesis. Arch Pathol Lab Med. 2005 Oct; 129(10):1299–310. PMID: 16196520
5. Graubert T, Walter MJ. Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program. 2011; 2011:543–9. doi: 10.1182/asheducation-2011.1.543 PMID: 22160087
6. Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol. 2003 Apr; 33(4):153–60. PMID: 12810828
7. Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 1998 Jun; 12(6):887–92. PMID: 9639416
8. Misawa S, Horike S, Kaneko H, Kashima K. Genetic aberrations in the development and subsequent progression of myelodysplastic syndrome. Leukemia. 1997 Apr; 11 Suppl 3:533–5. PMID: 9209448
9. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, et al. Piedmont Study Group on Myleodysplastic Syndromes. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol. 2003 May 15; 21(10):1988–95. PMID: 12743153
10. Kim M, Oh B, Kim SY, Park HK, Hwang SM, Kim TY, et al. p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study. Leuk Res. 2010 Jun; 34(6):718–22. doi: 10.1016/j.leukres.2009.09.007 PMID: 19782398
11. Boroiævic R, Roela RA, Rodarte RS, Thiago LS, Pasini FS, Conti FM, et al. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leuk Res. 2004 Aug; 28(8):831–44. PMID: 15203281
12. Flores-Figueroa E, Gutiérrez-Espínolía G, Montesinos JJ, Arana-Trejo RM, Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res. 2002 Jul; 26(7):677–86. PMID: 12008086
13. Raaijmakers MH. Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis. Int J Hematol. 2012 Jan; 95(1):17–25. doi: 10.1007/s12185-011-1001-x PMID: 22218882
14. Dührsen U, Hossfeld DK. Stromal abnormalities in neoplastic bone marrow diseases. Ann Hematol. 1996 Aug; 73(2):53–70. PMID: 8774614
15. Tauro S, Hepburn MD, Peddie CM, Bowen DT, Pippard MJ. Functional disturbance of marrow mesenchymal microenvironment in the myelodysplastic syndromes. Leukemia. 2002 May; 16(5):785–90. PMID: 11986938
16. Aizawa S, Nakano M, Iwase O, Yaguchi M, Hiramoto M, Hoshi H, et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res. 1999 Mar; 23(3):239–46. PMID: 10071075
17. Tauro S, Hepburn MD, Bowen DT, Pippard MJ. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica. 2001 Oct; 86(10):1038–45. PMID: 11602409
18. Roela RA, Carraro DM, Brentani HP, Kaiano JH, Simão DF, Guarnieiro R, et al. Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes. Leuk Res. 2007 May; 31(5):579–89. PMID: 17092558
19. Van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003 Dec; 17(12):2257–317. PMID: 14671650
20. Langerak AW, Groenen PJ, Brüggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012 Oct; 26(10):2159–71. doi: 10.1038/leu.2012.246 PMID: 22918122
21. Sandberg Y, van Gastel-Mol EJ, Verhaaf B, Lam KH, van Dongen JJ, Langerak AW. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J Mol Diagn. 2005 Oct; 7(4):495–503. PMID: 16237219
22. Klaus M, Stavroulaki E, Kastrinaki MC, Fragioudaki P, Giannikou K, Psyllaki M, et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in...
patients with myelodysplastic syndromes. Stem Cells Dev. 2010 Jul; 19(7):1043–54. doi: 10.1089/scd.
2009.0286 PMID: 19788374

23. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007 Nov; 262(5):509–25. PMID: 17949362

24. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008; 24(13):1547–8. doi: 10.1093/bioinformatics/btn224 PMID: 18467348

25. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011 Feb 1; 27(3):431–2. doi: 10.1093/bioinformatics/btq675 PMID: 21149340

26. Warsow G, Greber B, Falk SS, Harder C, Siatkowski M, Schordan S, Som A, Endlich N, Schölzer H, Repsilber D, Endlich K, Fuellen G. ExprEssence—revealing the essence of differential experimental data in the context of an interaction/regulation net-work. BMC Syst Biol. 2010 Nov 30; 4:164. doi: 10.1186/1755-0509-4-164 PMID: 2118483

27. Lottaz C, Yang X, Scheid S, Spang R. OrderedList—a bioconductor package for detecting similarity in ordered gene lists. Bioinformatics. 2006 Sep 15; 22(18):2315–6. PMID: 16844712

28. Servant N, Gravier E, Gestrraud P, Laurent C, Paccard C, Biton A, et al. EMA—a R package for Easy Microarray data analysis. BMC Res Notes. 2010 Nov 3; 3:277. doi: 10.1186/1756-0500-3-277 PMID: 21047405

29. Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011; 39(Web Server issue): W316–22. doi: 10.1093/nar/gkr483 PMID: 21715386

30. Croft D, Mundo AF, Haw R, Milacic M, Schordan S, Som A, Endlich N, Schölzer H, Repsilber D, Endlich K, Fuellen G. The Reactome pathway knowledgebase. Nucleic Acids Res. 2014 Jan; 42(Database issue):D437–42. doi: 10.1093/nar/gkt1102 PMID: 24243840

31. Kiełbasa SM, Klein H, Roider HG, Vingron M, Blüthgen N. TransFind—predicting transcriptional regulators for gene sets. Nucleic Acids Res. 2010 Jul; 38(Web Server issue): W275–80. doi: 10.1093/nar/gkq438 PMID: 20511592

32. Bhowmick NA, Nelson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004 Nov 18; 432(7015):332–7. PMID: 15549095

33. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006; 1:119–50. PMID: 18039110

34. Feng X, Scheinberg P, Wu CO, Samsel L, Nunez O, Prince C, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica. 2011. Apr 96(4):602–6. doi: 10.3324/haematol.2010.030536 PMID: 21180069

35. Suárez-Farías M, Noggi S, Heke M, Hemmati-Brivanlou A, Magnasco MO. Comparing independent microarray studies: the case of human embryonic stem cells. BMC Genomics. 2005 Jul 22; 6:99. PMID: 16042783

36. Nelson N, Marks MS, Driggers PH, Ozato K. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol Cell Biol. 1993 Jan; 13(1):588–99. PMID: 7678054

37. Ozato K, Tailor P, Kubota T. The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem. 2007 Jul 13; 282(28):20065–9. Epub 2007 May 14. PMID: 17502370

38. Contursi C, Wang IM, Gabriele L, Gadina M, O’Shea J, Morse HC 3rd, et al. IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNgamma-responsive promoters in macrophages. Proc Natl Acad Sci U S A. 2000 Jul 18; 97(1):332–7. Epub 2000 Jun 13. PMID: 10800165

39. Ferrer RA, Wobus M, List C, Wehner R, Schönefeldt C, Brocard B, et al. Mesenchymal stromal cells from patients with myelodysplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica. 2013 Nov; 98(11):1677–85. doi: 10.3324/haematol.2013.083972 PMID: 23716561
44. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia. 2010 Apr; 24(4):756–64. doi: 10.1038/leu.2010.31 PMID: 20220779

45. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013 Nov 21; 122(22):3616–27 doi: 10.1182/blood-2013-08-518886 PMID: 24030381

46. Abdel-Wahab O, Figueroa ME. Interpreting new molecular genetics in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2012; 2012:56–64. doi: 10.1182/asheducation-2012.1.56 PMID: 23235651

47. Brosseau JP, Lucier JF, Nwilati H, Thibault P, Garneau D, Gendron D, et al. Tumor microenvironment-associated modifications of alternative splicing. RNA. 2014 Feb; 20(2):189–201. doi: 10.1261/MA.042168.113 PMID: 24335142

48. D'Incalci M, Badri N, Galmarini CM, Allavena P, Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014 Aug 12; 111(4):646–50. doi: 10.1038/bjc.2014.149 PMID: 24755886

49. Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res. 2000 Feb; 24(2):141–51. PMID:10654450

50. Schildgen V, Wulfert M, Gattermann N. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. Exp Hematol. 2011 Jun; 39(6):666–675. doi: 10.1016/j.exphem.2011.03.007 PMID: 21447369

51. Sun H, Taneja R. Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4058–63. PMID:10737769

52. Hughes M, Dobric N, Scott IC, Su L, Starovic M, St-Pierre B, et al. The Hand1, Stra13 and Gcm1 transcription factors override FGF signaling to promote terminal differentiation of trophoblast stem cells. Dev Biol. 2004 Jul 1; 271(1):26–37. PMID: 15196947

53. Zheng Y, Jia Y, Wang Y, Wang M, Li B, Shi X, et al. The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in gastric cancer. OMICS. 2009 Aug; 13(4):301–6. doi: 10.1089/omi.2009.0014 PMID: 19624270

54. Chakrabarti J, Turley H, Campo L, Han C, Harris AL, Gatter KC, et al. The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. Br J Cancer. 2004 Aug 31; 91(5):954–8. PMID: 15328513

55. Ismail PM, Lu T, Sawadogo M. Loss of USF transcriptional activity in breast cancer cell lines. Oncogene. 1999 Sep 30; 18(40):5582–91. PMID: 10523835

56. Qyang Y, Luo X, Lu T, Ismail PM, Krylov D, Vinson C, et al. Cell-type-dependent activity of the ubiquitous transcription factor USF in cellular proliferation and transcriptional activation. Mol Cell Biol. 1999 Feb; 19(2):1508–17. PMID: 9891084

57. Pawlus MR, Wang L, Ware K, Hu CJ. Upstream stimulatory factor 2 and hypoxia-inducible factor 2α (HIF2α) cooperatively activate HIF2 target genes during hypoxia. Mol Cell Biol. 2012 Nov; 32(22):4595–610. doi: 10.1128/MCB.00724-12 PMID: 22966206

58. Choi H, Chun YS, Kim SW, Kim MS, Park JW. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol. 2006 Nov; 70(5):1664–71. PMID: 16880289

59. Ivanov SV, Salnikow K, Ivanova AV, Bai L, Lerman MI. Hypoxic repression of STAT1 and its downstream genes by a pHV/HIF-1 target DEC1/STRA13. Oncogene. 2007 Feb 8; 26(6):802–12. PMID: 16878149